Hearing disorder following COVID-19 vaccination: A pharmacovigilance analysis using the Vaccine Adverse Event Reporting System

Congqin Chen MPharm | Fang Fu PharmB | Lingqing Ding MPharm | Jie Xiao PharmB

Department of Pharmacy, Xiamen Cardiovascular Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China

Correspondence
Jie Xiao, Department of Pharmacy, Xiamen Cardiovascular Hospital of Xiamen University, 2999 Jinshan Road, Huli District, Xiamen, China.
Email: yfxjbz666@163.com

Abstract

What is known and objective: Evidence on whether the coronavirus disease 2019 (COVID-19) vaccination could cause hearing-related adverse events is still conflicting. This study aims to access the association between COVID-19 vaccine and hearing disorder.

Methods: The Vaccine Adverse Event Reporting System (VAERS) was queried between January 2020 to November 2021. The disproportionality pattern for hearing impairment of COVID-19 vaccine was accessed by calculating the reporting odds ratio (ROR) and proportional reporting ratio (PRR). A further subgroup analysis based on the type of COVID-19 vaccine and the doses administered was performed. In addition, the disproportionalities for hearing dysfunction between COVID-19 and influenza vaccines were compared.

Results and discussion: A total of 14,956 reports of hearing-related adverse events were identified with COVID-19 vaccination and 151 with influenza vaccine during the analytic period in VAERS. The incidence of hearing disorder following COVID-19 vaccination was 6.66 per 100,000. The results of disproportionality analysis revealed that the adverse events of hearing impairment, after administration of COVID-19 vaccine, was significantly highly reported (ROR 2.38, 95% confidence interval [CI] 2.20–2.56; PRR: 2.35, $\chi^2$ 537.58), for both mRNA (ROR 2.37, 95% CI 2.20–2.55; PRR 2.34, $\chi^2$ 529.75) and virus vector vaccines (ROR 2.50, 95% CI 2.28–2.73; PRR 2.56, $\chi^2$ 418.57). While the disproportional level for hearing dysfunction was quite lower in influenza vaccine (ROR 0.36, 95% CI 0.30–0.42; PRR 0.36, $\chi^2$ 172.24).

What is new and conclusion: This study identified increased risk for hearing disorder following administration of both mRNA and virus vector COVID-19 vaccines compared to influenza vaccination in real-world settings.

KEYWORDS
COVID-19 vaccine, hearing disorder, influenza vaccine, pharmacovigilance analysis, VAERS
1 | WHAT IS KNOWN AND OBJECTIVE

The spread of Coronavirus Disease 2019 (COVID-19) has imposed a heavy burden on public health as well as global economies.\(^1,2\) Vaccination is significantly essential to manage the COVID-19 pandemic.\(^3,4\) As of January 10, 2022, 9.43 billion doses of COVID-19 vaccine have been administered globally.\(^5\) With the increasing number of COVID-19 vaccine given, there are some reports of new-onset oto-logic symptoms, which were not listed as common potential Adverse Events following Immunization (AEFIs) during clinical trials. Shortly after vaccination against COVID-19 become available, some physicians have noticed an increased frequency of AEFI with hearing impairment, especially sudden sensorineural hearing loss (SSNHL), aural fullness and tinnitus.\(^6\) Although there are some published case reports regarding hearing loss after COVID-19 vaccination,\(^7,8\) the correlation between hearing impairment with COVID-19 vaccine is still unclear. Thus, to further evaluate the association between COVID-19 vaccine and hearing disorder, we performed a disproportionality analysis based on the Vaccines Adverse Event Reporting System (VAERS), which is a pharmacovigilance database used to monitor safety signals of vaccines.

2 | METHODS

2.1 | Data source

VAERS is a US spontaneous reporting system for AEFIs that is co-administered by the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA).\(^9,10\) VAERS accepts reports from vaccine manufacturers, health-care providers, vaccine recipients and others. The VAERS reports include information on age, sex, vaccines administered, dose and lot number, the AEFI experienced, and health history. Signs and symptoms of AEFI are coded by trained personnel using the Medical Dictionary for Regulatory Activities (MedDRA), a clinically validated, internationally standardized terminology.\(^9,11\) VAERS could be applied to detect unexpected patterns of AEFI, which are unlikely to be detected in clinical trials because of the limited number of vaccine recipients involved.\(^12-16\)

2.2 | Data extraction

Reports for individuals receiving any type of vaccine against the COVID-19 or influenza virus categorized as suspect AEFI submitted to VAERS (from January 2020 to November 2021) were selected. Cases of hearing impairment were extracted through specific preferred terms (PTs) according to the MedDRA version 20.1. The standardized MedDRA Queries (SMQ) are groupings of MedDRA terms, ordinarily at the PT level that relate to a defined medical condition or area of interest. We utilized 51 terms that matched the SMQ for “hearing impairment” (SMQ code: 20000171) (Table S1). Data such as age, sex, recovery, and onset interval (from vaccination date [day 0] to the reported onset of first symptom) were also collected.

2.3 | Disproportionality analysis

Disproportionality analysis is largely used to identify statistical associations between drugs/vaccines and events in their respective databases of safety reports.\(^17\) If there is no link between a vaccine and an AEFI, the frequency of such AEFI will be uniformly distributed in reports listing and in those not listing the specific vaccine as suspect, thus without disproportionality. On the contrary, AEFIs that are caused by a vaccine will occur more frequently in reports listing than in those not listing the vaccine as suspect, thus generating disproportionality.\(^18\) Proportional Reporting Ratio (PRR) is a simple way to measure the strength of the statistical association between a specific vaccine and a specific AE. This concept of disproportionality may be displayed by means of a \(2 \times 2\) contingency table where: “a” is all reports for a specific adverse event (“Event Y”) for Product (e.g., a vaccine) X, “b” is all reports for all other adverse events for Product X, “a + b” are all the reports for Product X, “c” is all reports for all other products for Event Y, “d” is all reports for all other products for all other adverse event, and “c + d” is all reports for all products. The PRR = \([a/(a+b)]/[c/(c+d)]\). If the ratio of \([a/(a+b)]\) is greater than the ratio of \([c/(c+d)]\), then Event Y is “disproportionately reported” for Product X. A signal was defined as a PRR of at least 2, \(\chi^2\) of at least 4 in three or more cases.\(^19\) The Reporting Odds Ratio (ROR) is the odds of a certain event occurring with a specific vaccine, compared to the odds of the same event occurring with all other vaccines. The ROR = \((ad/cb)\).\(^20\) A signal emerged if the lower limits of the 95% confidence intervals (95% CI) of ROR exceeded 1 in at least three records.\(^21\)

2.4 | Study design

This study was determined to be exempt from institutional review board approval by Xiamen Cardiovascular Hospital because it used publicly available, deidentified data. A pharmacovigilance analysis was conducted to access the association between COVID-19 vaccine and hearing disorder. The disproportionality pattern of hearing impairment for COVID-19 vaccine within VAERS was accessed by calculating ROR and PRR. We performed a further subgroup analysis based on the type of COVID-19 vaccine (mRNA vs. virus vector) and the doses administered. In addition, to better understand the association of COVID-19 vaccination and hearing impairment, we compared the disproportionality between COVID-19 vaccine and influenza vaccine.

3 | RESULTS

3.1 | Descriptive analysis

As of November 10, at least 224,660,453 people or 68.44% of the population in U.S. have received at least one dose of COVID-19 vaccine.\(^22\) Overall, 654,413 AEFIs related to COVID-19 vaccine and 15,670 reports related to hearing impairment were documented in
the VAERS database during the analytic period. Among them, COVID-19 vaccination was identified as the suspected vaccine causing hearing impairment in 14,956 reports and the clinical characteristics of these vaccine recipients are presented in Table 1. AEFI of hearing impairment following COVID-19 vaccination was found with an incidence rate of 6.66 per 100,000. Most of the reports were from administration of mRNA vaccine (90.40%). Females accounted for 9066 (60.62%) reports, males accounted for 5670 (37.91%) reports, and in 220 (1.47%) reports, sex was unknown or not reported. In reports in which age was documented (n = 14,305), most (n = 6840, 47.82%) described persons aged 45 to 64 years. Notably, cases of hearing impairment were more common after the administration of the first dose of vaccine (51.68%). Most of the reports (72.54%) did not recover from hearing-related AEFI in time.

### 3.2 Disproportionality analysis

The results of disproportionality analysis are summarized in Table 2. These revealed significantly high reporting of hearing impairment following the administration of COVID-19 vaccine (ROR 2.38, 95% CI 2.20–2.56; PRR: 2.35, chi-square 537.58). Influenza vaccine showed a lower ROR of 0.36 (95% CI 0.30–0.42) and a lower PRR of 0.36 ($\chi^2$ 172.24), demonstrating that in comparison to COVID-19 vaccine, influenza vaccine was not associated with signal of hearing impairment. We conducted separate sub-analysis based on the type of COVID-19 vaccine and the dose administered. Both mRNA and virus vector vaccines were significantly associated with increased risk for hearing disorder compared to all other vaccines from VAERS (mRNA: ROR 2.37 95% CI 2.20–2.55, PRR 2.34 $\chi^2$ 529.75; virus vector:

### Table 1 Characteristics of reports to the VAERS following COVID-19 vaccination by hearing impairment

| Characteristics | Reports, n (%) |
|-----------------|----------------|
| mRNA (PfizerBioNTech + Moderna) | Virus vector (Johnson & Johnson’s Janssen) | Mixed vaccination | Not specified | Total |
| **N (%)** | 13,520 (90.40) | 1414 (9.45) | 1 (0.01) | 21 (0.14) | 14,956 |
| **Age (years)** | | | | | |
| <18 | 283 (2.09) | 0 (0) | 0 (0) | 0 (0) | 283 (1.89) |
| 18–44 | 3884 (28.73) | 530 (37.48) | 0 (0) | 7 (33.33) | 4421 (29.56) |
| 45–64 | 6180 (45.71) | 648 (45.83) | 1 (100) | 11 (52.38) | 6840 (45.73) |
| ≥65 | 2618 (19.36) | 140 (9.90) | 0 (0) | 3 (14.29) | 2761 (18.46) |
| Not specified | 555 (4.11) | 96 (6.79) | 0 (0) | 0 (0) | 651 (4.35) |
| **Sex** | | | | | |
| Male | 5115 (37.83) | 548 (38.76) | 0 (0) | 7 (33.33) | 5670 (37.91) |
| Female | 8231 (60.88) | 820 (57.99) | 1 (100) | 14 (66.67) | 9066 (60.62) |
| Not specified | 174 (1.29) | 46 (3.25) | 0 (0) | 0 (0) | 220 (1.47) |
| **Dose** | | | | | |
| First | 6772 (50.09) | 943 (66.69) | 1 (100) | 14 (66.67) | 7730 (51.68) |
| Second | 4707 (34.82) | 3 (0.21) | 0 (0) | 0 (0) | 4710 (31.49) |
| Third | 221 (1.63) | – | 0 (0) | 0 (0) | 221 (1.48) |
| Not specified | 1820 (13.46) | 468 (33.10) | 0 (0) | 7 (33.33) | 2295 (15.35) |
| **Recovering** | | | | | |
| Recovered | 1761 (13.03) | 270 (19.09) | 0 (0) | 6 (28.57) | 2037 (13.62) |
| Not recovered | 9892 (73.17) | 942 (66.62) | 1 (100) | 14 (66.67) | 10,849 (72.54) |
| Not specified | 1867 (13.81) | 202 (14.29) | 0 (0) | 1 (4.76) | 2070 (13.84) |

### Table 2 Results of disproportionality analysis

| Vaccines | Cases | ROR (95%CI) | PRR ($\chi^2$) |
|----------|-------|-------------|----------------|
| COVID-19 vaccines | 14,956 | 2.38 (2.20–2.56) | 2.35 (537.58) |
| mRNA | 13,520 | 2.37 (2.20–2.55) | 2.34 (529.75) |
| 1st dose | 6772 | 2.37 (2.19–2.56) | 2.34 (506.07) |
| 2nd dose | 4707 | 2.50 (2.31–2.71) | 2.47 (551.20) |
| 3rd dose | 221 | 1.30 (1.12–1.52) | 1.30 (11.86) |
| Unspecified dose | 1820 | 2.26 (2.07–2.47) | 2.24 (356.05) |
| Virus vector | 1414 | 2.50 (2.28–2.73) | 2.56 (418.57) |
| 1st dose | 943 | 2.99 (2.71–3.30) | 2.93 (525.20) |
| 2nd dose | 3 | 0.80 (0.26–2.51) | 0.81 (0.14) |
| Unspecified dose | 468 | 1.90 (1.69–2.13) | 1.88 (117.86) |
| Influenza vaccines | 151 | 0.36 (0.30–0.42) | 0.36 (172.24) |

Abbreviations: 95%CI, 95% confidence interval; COVID-19, coronavirus disease 2019; PRR, proportional reporting ratio; ROR, reporting odds ratio.
ROR 2.50, 95% CI 2.28–2.73, *P* = .0001. For mRNA vaccines, the ROR was highest in dose 2 (2.50, 95% CI 2.31–2.71), then it decreased to 2.37 (95% CI 2.19–2.56) in dose 1 and 1.30 (95% CI 1.12–1.52) in dose 3. The PRR reached peak in dose 2 (2.47, *P* < .0001), then it decreased to 2.34 (*P* = .15) in dose 1 and 1.30 (*P* = .05) in dose 3. For virus vector vaccines, dose 1 was disproportionately associated with AEs of hearing loss with ROR of 2.99 (95% CI 2.71–3.30) and PRR of 2.93 (*P* < .0001), while the disproportional values were quite lower in dose 2 (ROR 0.80, 95% CI 0.26–2.51, PRR 0.81, *P* = .76).

### 3.3 | Time to onset of COVID-19 vaccine-associated hearing impairment

The times to onset following each type and dose of COVID-19 vaccines are shown in Table 3. Interestingly, it can be seen from the data that the AEs of hearing impairment occurred as soon as after administration of all types of COVID-19 vaccination. For mRNA vaccines, 8047 (59.52%) cases of hearing impairment occurred within 3 days and 1509 (11.16%) cases on day 4–7 after vaccination. For virus vector vaccines, 5898% of the cases occurred within 3 days and 9.12% on day 4–7 following administration.

### 4 | DISCUSSION

To the best of our knowledge, this is the first real-world disproportionality study investigating the risk of hearing impairment following COVID-19 vaccination by assessing spontaneous reports submitted to the VAERS. This post-marketing safety study stems from recent conflicting evidence surrounding the possible sudden-onset hearing loss after immunization, especially COVID-19 vaccination, and the ongoing debate on the relationship between COVID-19 vaccination and hearing impairment.

Three major findings emerged from our study: (a) Hearing impairment was reported relatively frequently retrieved in VAERS and the COVID-19 vaccination coverage rate in the US. (b) Comparing to influenza vaccine, COVID-19 vaccination had higher ROR and PRR. (c) The AEs of hearing loss occurred as soon as after administration of COVID-19 vaccination.

Narrow PTs (sudden hearing loss, deafness, deafness unilateral, deafness neurosensorial, and hypacusis) were utilized to identify AEs of hearing loss in this study. As the number of COVID-19 vaccine doses increased, more and more reports of other otologic manifestations such as tinnitus, aural fullness, and dysacusis were noticed. With this correspondence, we suspect that the number of other otologic manifestations given increased. With this correspondence, we suspect that the number of other otologic manifestations given increased.
performed a broad SMQ search for “hearing impairment” with 51 related PTs, which identified more reports and resulted in a slightly higher incidence. To be noted, hearing impairment represented a very rare AEFI in both studies with an incidence of <0.01% according to the CIOMS criteria.\textsuperscript{26} Still, the pattern of “very rare” does not by itself prove no association.

During clinical trials, otologic symptoms such as hearing loss were not listed as common potential AEFIs for COVID-19 vaccine.\textsuperscript{27,28} Due to the known limitations of clinical trials to detect particularly rare adverse events and an increase in patients present with hearing loss noticed in otologic practice,\textsuperscript{6} we utilized VAERS, a post-marketing safety database of vaccine, to detect signals of hearing impairment. Long before COVID-19 vaccine, anecdotal case reports of SSNHL following other vaccines have led to a speculation that vaccination might be the cause of hearing loss in some cases.\textsuperscript{29,30} Baxer and colleagues performed a large-scale case control study to analyse for an association between SSNHL and vaccinations.\textsuperscript{21} The odds ratios for vaccination to SSNHL were 0.965 (95% CI, 0.61–1.50) for influenza vaccine, 0.842 (95% CI 0.39–1.62) for tetanus, and 0.454 (95% CI 0.08–1.53) for zoster vaccine, demonstrating no association between these vaccination and the rate of SSNHL. Given the fact that influenza vaccine has been deemed acceptably safe since they have undergone thorough safety evaluations in the form of continued population-based post-market surveillance,\textsuperscript{31,32} we set it as the control group to compare the disproportionality pattern. Similarly, our results showed a lower ROR of 0.36 (95% CI: 0.30–0.42) and PRR of 0.36 ($\chi^2$) for influenza vaccine, demonstrating no association with signal of hearing related disorder, while signal of disproportionate reporting for COVID-19 vaccine was found, indicating there might be a risk of hearing impairment following vaccination of COVID-19.

As of today, there are currently three COVID-19 vaccines available in US, Pfizer-BioNTech, Moderna and Janssen COVID-19 vaccine.\textsuperscript{33} Among them, Janssen is a virus vector vaccine, while Pfizer-BioNTech and Moderna are mRNA vaccines based on new technologies that have not been deployed to the general population. So far, there have been several case reports of hearing loss following vaccination of Pfizer-BioNTech vaccine published.\textsuperscript{7,22} Wichova et al.\textsuperscript{6} reported 30 patients who had new or significantly exacerbated otologic symptoms that began shortly after COVID-19 vaccination, among them, 18 patients received Moderna and 12 patients received Pfizer vaccine. To specify whether the technique of vaccine play a role in hearing risk, we conducted a sub-group analysis based on the vaccine type, which showed both mRNA and virus vector COVID-19 vaccines were associated with adverse event of hearing impairment.

The hearing disorder is more common in female and middle-aged people (45–64 years) in our study. The pattern is different from the demographic characteristics in wider population based on a cross-sectional analysis, in which hearing loss was more pronounced in male and the elderly.\textsuperscript{34} The influence of sex and age deserves further studies. Time to onset of COVID-19 vaccine-associated hearing impairment was explored too. Results showed that >50% of the reports experienced hearing-related symptoms within 3 days after vaccination. Oddly, most of the reports did not recover in time.

The hearing disorder is more common in female and middle-aged people (45–64 years) in our study. The pattern is different from the demographic characteristics in wider population based on a cross-sectional analysis, in which hearing loss was more pronounced in male and the elderly.\textsuperscript{34} The influence of sex and age deserves further studies. Time to onset of COVID-19 vaccine-associated hearing impairment was explored too. Results showed that >50% of the reports experienced hearing-related symptoms within 3 days after vaccination. Oddly, most of the reports did not recover in time.
and audiovestibular symptoms.\textsuperscript{34–37} For those reports combined with confirmed or suspect COVID-19 infection, it was hard to distinguish whether the side effects were caused by vaccines or COVID-19 itself. Eighty-eight out of 14,956 reports were with combination of COVID-19 infection in our study, this proportion may not be significant to affect the disproportional pattern of hearing impairment to COVID-19 vaccine. Still, all reports are submitted to VAERS without specific causality assessed considering the events may be coincidental and related to other causes. The inability to make causal inference is a limitation of all pharmacovigilance studies. Notwithstanding these limitations, disproportionality analysis still represents an invaluable method to monitor vaccine safety and identify novel rare signals. Many initial warnings about vaccine safety are primed by a disproportionality in the VAERS.\textsuperscript{12–16}

5 WHAT IS NEW AND CONCLUSION

In conclusion, this study found increased risk for hearing disorder following administration of both mRNA and virus vector COVID-19 vaccines. Further observational studies are required to verify the causality. Health care providers are urged to rigorously report all possible otologic adverse events to VAERS to allow identification of systematic vaccine safety studies and sentinel trends.

ACKNOWLEDGEMENTS

We thank Xiaoshan Yu, MD, pharmacovigilance specialist, for her role in reviewing disproportionality analysis.

CONFLICT OF INTEREST

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

DATA AVAILABILITY STATEMENT

The data supporting the conclusion of this article will be made available from the corresponding authors upon reasonable request.

ORCID

Congqin Chen https://orcid.org/0000-0003-1768-1298
Fang Fu https://orcid.org/0000-0003-2768-0539
Lingqing Ding https://orcid.org/0000-0003-3604-6249
Jie Xiao https://orcid.org/0000-0002-2871-4086

REFERENCES

1. Salian VS, Wright JA, Vedell PT, et al. COVID-19 transmission, current treatment, and future therapeutic strategies. Mol Pharm. 2021;18(3):754-771.
2. Kannan S, Shaik Syed Ali P, Sheeza a, Hemalatha K. COVID-19 (novel coronavirus 2019)—recent trends. Eur Rev Med Pharmacol Sci. 2020; 24(4):2006-2011.
3. Soleimanpour S, Yaghoubi A. COVID-19 vaccine: where are we now and where should we go? Expert Rev Vaccines. 2021;20(1):23-44.
4. Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infec Dis. 2021;21(2):e26-e35.
5. Mattei E, Ritchie H, Ortiz-Ospina E, et al. A global database of COVID-19 vaccinations. Nat Hum Behav. 2021. https://ourworldindata.org/covid-vaccinations. Accessed January, 10, 2022.
6. Wichova H, Miller ME, Derebery MJ. Otologic manifestations after COVID-19 vaccination: the house ear clinic experience. Otol Neurotol. 2021;42(9):e1213-e1218.
7. Jeong J, Choi HS. Sudden sensorineural hearing loss after COVID-19 vaccination. Int J Infect Dis. 2021;113:341-343.
8. Tsetsos N, Poutoglidos A, Vlachitsis K, Kilipasanis A, Gougousis S. Sudden sensorineural hearing loss following the second dose of COVID-19 vaccine. Currus. 2021;13(8):e1743S.
9. Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the vaccine adverse event reporting system (VAERS). Vaccine. 2015;33(36):4398-4405.
10. Zhou W, Pool V, Iskander JK, et al. Surveillance for safety after immunization: vaccine adverse event reporting system (VAERS)-United States, 1991-2001. MMWR Surveill Summ. 2003;52(1):1-24.
11. CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine—United States, December 14–23, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(2):46-51.
12. Miller ER, McNeil MM, Moro PL, Duffy J, Su JR. The reporting sensitivity of the vaccine adverse event reporting system (VAERS) for anaphylaxis and for Guillain-Barré syndrome. Vaccine. 2020;38(47):7458-7463.
13. Su JR, McNeil MM, Welsh KJ, et al. Myopericarditis after vaccination, vaccine adverse event reporting system (VAERS), 1990-2018. Vaccine. 2021;39(5):839-845.
14. Moro PL, Woo EJ, Marquez P, Cano M. Monitoring the safety of high-dose, trivalent inactivated influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011-2019. Vaccine. 2020; 38(37):5923-5926.
15. Mei R, Raschi E, Forbes D, Diemenger I, De Ponti F, Poluzzi E. Myocarditis and pericarditis after immunization: gaining insights through the vaccine adverse event reporting system. Int J Cardiol. 2018;273:183-186.
16. Hibbs BF, Ng CS, Museru O, et al. Reports of atypical shoulder pain and dysfunction following inactivated influenza vaccine, vaccine adverse event reporting system (VAERS), 2010-2017. Vaccine. 2020;38(5):1137-1143.
17. Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72(6):905-908.
18. Almenoff JS, Pattishall EN, Gibbs TG, DuMouchel W, Evans SJW, Yuen N. Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther. 2007;82(2):157-166.
19. Mali G, Abuja V, Dubey K. Glucagon-like peptide-1 analogues and thyroid cancer: an analysis of cases reported in the European pharmacovigilance database. J Clin Pharm Ther. 2021;46(1):99-105.
20. Hosohata K, Inada A, Oyama S, Furushima D, Yamada H, Iwanaga K. Surveillance of drugs that most frequently induce acute kidney injury: a pharmacovigilance approach. J Clin Pharm Ther. 2019;44(1):49-53.
21. Zhai Y, Ye X, Hu F, et al. Updated insights on cardiac and vascular risks of proton pump inhibitors: a real-world pharmacovigilance study. Front Cardiovasc Med. 2022;9:767987.
22. USAFacts. US Coronavirus vaccine tracker. https://usafacts.org/visualizations/covid-vaccine-tracker-states/. Accessed November, 2021.
23. Baxter R, Lewis N, Bohrer P, Harrington T, Aukes L, Klein NP. Sudden-onset sensorineural hearing loss after immunization: a case-
centered analysis. *Otolaryngol Head Neck Surg.* 2016;155(1):81-86.

24. Formeister EJ, Chien W, Agrawal Y, Carey JP, Stewart CM, Sun DQ. Preliminary analysis of association between COVID-19 vaccination and sudden hearing loss using US Centers for Disease Control and Prevention vaccine adverse events reporting system data. *JAMA Otolaryngol Head Neck Surg.* 2021;147(7):674-676.

25. Filippatos F, Tatsi EB, Drellis C, Dessypris N, Syriopoulou V, Michos A. Association of clinical and epidemiological characteristics with COVID-19 BNT162b2 mRNA vaccine short-term adverse reactions in healthcare workers. *Hum Vaccin Immunother.* 2021;30:1-6.

26. Schutte T, Van Eekeren R, Richir M, et al. The adverse drug reaction reporting assignment for specialist oncology nurses: a preliminary evaluation of quality, relevance and educational value in a prospective cohort study. *Naunyn Schmiedeberg's Arch Pharmacol.* 2018;391(1):17-26.

27. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N Engl J Med.* 2020;383(27):2603-2615.

28. Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *Lancet Infect Dis.* 2021;21(2):181-192.

29. Bonfils P, Blacabe B, Potard G, Aidan D. Fluctuant perception hearing loss after hepatitis B vaccine. *Ann Otolaryngol Chir Cervicofac.* 1996;113(6):359-361.

30. Okhovat S, Fox R, Magill J, Narula A. Sudden onset unilateral sensorineural hearing loss after rabies vaccination. *BMJ Case Rep.* 2015;2015:bcr2015211977.

31. Yamayoshi S, Kawaoka Y. Current and future influenza vaccines. *Nat Med.* 2019;25(2):212-220.

32. Liang XF, Li L, Liu DW, et al. Safety of influenza a (H1N1) vaccine in postmarketing surveillance in China. *N Engl J Med.* 2011;364(7):638-647.

33. Mouffak S, Shubbar Q, Saleh E, El-Awady R. Recent advances in management of COVID-19: a review. *Biomed Pharmacother.* 2021;143:112107.

34. Alexander TH, Harris JP. Incidence of sudden sensorineural hearing loss. *Otol Neurotol.* 2013;34(9):1586-1589.

35. Choi A, Koch M, Wu K, et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. *Nat Med.* 2021;27(11):2025-2031.

36. Koumpa FS, Forde CT, Manjaly JG. Sudden irreversible hearing loss post COVID-19. *BMJ Case Rep.* 2020;13(11):e238419.

37. Karimi-Galougahi M, Naeini AS, Raad N, Mikaniki N, Ghorbani J. Vertigo and hearing loss during the COVID-19 pandemic—is there an association? *Acta Otorhinolaryngol.* 2020;40(6):463-465.

38. Degen C, Lenarz T, Willenborg K. Acute profound sensorineural hearing loss after COVID-19 pneumonia. *Mayo Clin Proc.* 2020;95(8):1801-1803.

39. Maharaj S, Bello Alvarez M, Mungul S, Hari K. Otologic dysfunction in patients with COVID-19: a systematic review. *Laryngoscope Investig Otolaryngol.* 2020;5(6):1192-1196.

40. Skarzynska MB, Matusiak M, Skarzynski PH. Adverse audio-vestibular effects of drugs and vaccines used in the treatment and prevention of COVID-19: a review. *Audiol Res.* 2022;12(3):224-248.

41. Sato K, Mano T, Niimi Y, Toda T, Iwata A, Iwatsubo T. Facial nerve palsy following the administration of COVID-19 mRNA vaccines: analysis of a self-reporting database. *Int J Infect Dis.* 2021;111:310-312.

**SUPPORTING INFORMATION**

Additional supporting information can be found online in the Supporting Information section at the end of this article.

_How to cite this article:_ Chen C, Fu F, Ding L, Xiao J. Hearing disorder following COVID-19 vaccination: A pharmacovigilance analysis using the Vaccine Adverse Event Reporting System. _J Clin Pharm Ther._ 2022;47(11):1789-1795. doi:10.1111/jcpt.13767